Healthcare provider profile · identity verified

Mark R Paulson, MD

Family Practice · PERHAM, MN · NPI 1295766392

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	516	144
Metoprolol Succinate	Metoprolol Succinate	360	111
Rosuvastatin Calcium	Rosuvastatin Calcium	333	98
Lisinopril	Lisinopril	278	82
Omeprazole	Omeprazole	251	81
Levothyroxine Sodium	Levothyroxine Sodium	195	52
Amlodipine Besylate	Amlodipine Besylate	185	54
Losartan Potassium	Losartan Potassium	183	53
Gabapentin	Gabapentin	165	40
Tamsulosin Hcl	Tamsulosin Hcl	138	44
Pantoprazole Sodium	Pantoprazole Sodium	136	37
Eliquis	Apixaban	124	28
Metformin Hcl	Metformin Hcl	118	32
Finasteride	Finasteride	109	33
Montelukast Sodium	Montelukast Sodium	99	27
Furosemide	Furosemide	93	27
Allopurinol	Allopurinol	92	25
Atenolol	Atenolol	77	20
Metformin Hcl Er	Metformin Hcl	77	26
Fluticasone Propionate	Fluticasone Propionate	76	27
Famotidine	Famotidine	70	18
Carvedilol	Carvedilol	68	18
Donepezil Hcl	Donepezil Hcl	68	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	19
Potassium Chloride	Potassium Chloride	67	13
Sertraline Hcl	Sertraline Hcl	65	19
Metoprolol Tartrate	Metoprolol Tartrate	63	17
Baclofen	Baclofen	59	11
Jardiance	Empagliflozin	59	13
Bumetanide	Bumetanide	57	20
Simvastatin	Simvastatin	54	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	19
Clopidogrel	Clopidogrel Bisulfate	50	13
Albuterol Sulfate Hfa	Albuterol Sulfate	49	20
Citalopram Hbr	Citalopram Hydrobromide	49	14
Spironolactone	Spironolactone	43	12
Bupropion Xl	Bupropion Hcl	42	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	39	15
Warfarin Sodium	Warfarin Sodium	39	16
Oxybutynin Chloride Er	Oxybutynin Chloride	38	11
Duloxetine Hcl	Duloxetine Hcl	36	11
Arexvy	Rsvpref3 Antigen/As01e/Pf	35	35
Trulicity	Dulaglutide	34	suppressed
Glipizide	Glipizide	32	suppressed
Prednisone	Prednisone	31	13
Hydrochlorothiazide	Hydrochlorothiazide	29	suppressed
Memantine Hcl	Memantine Hcl	29	suppressed
Meloxicam	Meloxicam	27	suppressed
Trazodone Hcl	Trazodone Hcl	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Glipizide Er	Glipizide	23	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	22	22
Enalapril Maleate	Enalapril Maleate	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	15
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	20	13
Xarelto	Rivaroxaban	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Ozempic	Semaglutide	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	14
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Amiodarone Hcl	Amiodarone Hcl	17	suppressed
Arnuity Ellipta	Fluticasone Furoate	17	suppressed
Digoxin	Digoxin	17	suppressed
Flecainide Acetate	Flecainide Acetate	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Topiramate	Topiramate	17	suppressed
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Lamotrigine	Lamotrigine	16	suppressed
Metronidazole	Metronidazole	16	suppressed
Raloxifene Hcl	Raloxifene Hcl	16	suppressed
Sotalol	Sotalol Hcl	16	suppressed
Brilinta	Ticagrelor	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	13	13
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	11
Azithromycin	Azithromycin	12	suppressed
Metolazone	Metolazone	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error